Form 4 · Statement of Changes in Beneficial Ownership · Filed 2026-07-01
Connaughton Bernadette Files Halozyme Therapeutics (HALO) Form 4 - July 01, 2026
Connaughton Bernadette sold 1.6K HALO shares worth $124.7K in this Form 4 filing, reported to the SEC on 2026-07-01.
- Insider
- Connaughton Bernadette
- Issuer
- Halozyme Therapeutics Inc. HALO · NASDAQ
- Filed
- Period
- 2026-07-01
- Accession
- 0001159036-26-000094
- Source
- Official filing on sec.gov ↗
Transactions (2)
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Connaughton Bernadette | 2026-07-01 | Sell | 1.0K | $76.39 | $76.4K | Direct |
| Connaughton Bernadette | 2026-07-01 | Sell | 625 | $77.21 | $48.3K | Direct |
| Net change | −1.6K | −$124.7K | ||||
About Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc. is a biopharmaceutical company that specializes in developing and commercializing treatments focused on enhanced subcutaneous drug delivery. The company's proprietary technology, ENHANZE, aims to improve the efficacy and convenience of existing therapies by facilitating faster drug absorption and reducing the need for intravenous administration. Halozyme partners with major pharmaceutical companies to integrate its technology with a variety of treatments, significantly impacting the oncology, immunology, and genetic disorder sectors. This collaboration model helps expand the reach of its technology across multiple therapeutic applications. Based in San Diego, California, Halozyme is noted for its innovative approach to drug delivery, contributing to the broader pharmaceutical industry's efforts to improve patient experiences and optimize medical outcomes. As a significant player in the biopharmaceutical landscape, Halozyme's advancements continue to drive interest and growth within the market, underscoring the vital role of drug delivery technology in modern medicine.
Track HALO insider activity
Get alerted when Halozyme Therapeutics Inc. executives buy or sell their shares.